Winald R Gerritsen

8PUBLICATIONS
68CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersMolecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Feb 23, 2024
Adjuvant dendritic cell therapy in stage IIIB/C melanoma: the MIND-DC randomized phase III trial.

Kalijn F Bol, Gerty Schreibelt, Martine Bloemendal

|Mar 05, 2022
Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results from the KEYNOTE-045 and KEYNOTE-052 Landmark Trials.

Joaquim Bellmunt, Ronald de Wit, Yves Fradet

|Feb 17, 2022
Convection Enhanced Delivery of the Oncolytic Adenovirus Delta24-RGD in Patients with Recurrent GBM: A Phase I Clinical Trial Including Correlative Studies.

Erik H P van Putten, Anne Kleijn, Victor W van Beusechem

|Jan 20, 2022
Responsiveness to Immune Checkpoint Inhibitors Is Associated With a Peripheral Blood T-Cell Signature in Metastatic Castration-Resistant Prostate Cancer.

Donjete Simnica, Minke Smits, Edith Willscher

|Sep 28, 2021
Whole Blood Transcriptome Profiling Identifies DNA Replication and Cell Cycle Regulation as Early Marker of Response to Anti-PD-1 in Patients with Urothelial Cancer.

Sandra van Wilpe, Victoria Wosika, Laura Ciarloni

|Jun 01, 2021
A tipping point in cancer-immune dynamics leads to divergent immunotherapy responses and hampers biomarker discovery.

Jeroen H A Creemers, W Joost Lesterhuis, Niven Mehra

Pageof 2

Frequent Collaborators

4 joint publications

I Jolanda M de Vries

3 joint publications

Carl G Figdor

3 joint publications

Niven Mehra

2 joint publications

Johannes Textor